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Abstract
Background: Prior evidence suggests that the renin angiotensin system and antihypertensives that
inhibit this system play a role in cognitive, central vascular, and endothelial function. Our objective
is to conduct a double-blind randomized controlled clinical trial, the antihypertensives and vascular,
endothelial, and cognitive function (AVEC), to compare 1 year treatment of 3 antihypertensives
(lisinopril, candesartan, or hydrochlorothiazide) in their effect on memory and executive function,
cerebral blood flow, and central endothelial function of seniors with hypertension and early
objective evidence of executive or memory impairments.
Methods/Design: The overall experimental design of the AVEC trial is a 3-arm double blind
randomized controlled clinical trial. A total of 100 community eligible individuals (60 years or older)
with hypertension and early cognitive impairment are being recruited from the greater Boston area
and randomized to lisinopril, candesartan, or hydrochlorothiazide ("active control") for 12 months.
The goal of the intervention is to achieve blood pressure control defined as SBP < 140 mm Hg and
DBP < 90 mm Hg. Additional antihypertensives are added to achieve this goal if needed. Eligible
participants are those with hypertension, defined as a blood pressure 140/90 mm Hg or greater,
early cognitive impairment without dementia defined (10 or less out of 15 on the executive clock
draw test or 1 standard deviation below the mean on the immediate memory subtest of the
repeatable battery for the assessment of neuropsychological status and Mini-Mental-Status-exam
>20 and without clinical diagnosis of dementia or Alzheimer's disease). Individuals who are
currently receiving antihypertensives are eligible to participate if the participants and the primary
care providers are willing to taper their antihypertensives. Participants undergo cognitive
assessment, measurements of cerebral blood flow using Transcranial Doppler, and central
endothelial function by measuring changes in cerebral blood flow in response to changes in end tidal
carbon dioxide at baseline (off antihypertensives), 6, and 12 months. Our outcomes are change in
cognitive function score (executive and memory), cerebral blood flow, and carbon dioxide cerebral
vasoreactivity.
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Discussion: The AVEC trial is the first study to explore impact of antihypertensives in those who
are showing early evidence of cognitive difficulties that did not reach the threshold of dementia.
Success of this trial will offer new therapeutic application of antihypertensives that inhibit the renin
angiotensin system and new insights in the role of this system in aging.
Trial Registration: Clinicaltrials.gov NCT00605072
Background
In addition to its role in developing cardiovascular disease
and stroke, hypertension is also a risk factor for cognitive
impairment [1-5] Although blood pressure tends to
decline around the time of onset of clinical cognitive
impairment[3], hypertension leads to accelerated decline
in those with cognitive impairment or dementia[6,7] Of
all the cognitive domains, executive function is more vul-
nerable to the effects of hypertension [8-10] Executive
function is defined as the set of cognitive skills that are
responsible for the planning, initiation, sequencing, and
monitoring of complex goal-directed behavior[11] Sen-
iors suffering from executive dysfunction have significant
impairment in following medical advise [12] and are
more likely to develop disability[13,14] It is estimated
that close to 30% of the elderly population have executive
function abnormalities and are generally undetec-
ted[15,16] No prior research has evaluated the effect of
hypertension treatment on executive function or specifi-
cally enrolled those with executive dysfunction.
The process by which hypertension can affect cognitive
and executive function is not clear. It is likely to be, in
part, related to the cerebral blood flow (CBF) regulatory
system. This is supported by the evidence that lower CBF
measured by Transcranial Doppler (TCD) is associated
with progressive decline in cognitive function[17] For
example, in patients with amnestic mild cognitive impair-
ment, lower CBF was associated with a higher risk for con-
verting to dementia[18] Further, abnormal
cerebrovascular reactivity was associated with worsening
cognitive decline in patients with Alzheimer's disease[19]
Hypertension is associated with a decrease in CBF over
and above any effect of age [20-23] Hypertension also
impairs neurovascular coupling[24] and vasoreactivity to
CO2, a measure of brain endothelial function[25] Taken
together, this provides a rational for investigating the role
of CBF regulation in the relation between hypertension
and cognitive function.
From a neuro-humoral standpoint, multiple systems may
be involved in the relation between hypertension and cog-
nitive function. However, a paucity of evidence point to
the renin angiotensin system (RAS). Anatomically, angi-
otensin II (Ang II) and its receptors are located in neurons
inside the blood brain barrier and in the cerebrovascular
endothelial cells and circumventricular organs[26] Func-
tionally, Ang II has been linked with cognitive function in
animal models[27] In addition, Ang II also decreases cer-
ebral blood flow[28] and impairs neurovascular cou-
pling[29] in hypertensive patients.
Ang II impairs endothelial function, which has been
linked to poor cognitive function and early Alzheimer's
disease [30-33] The role of the endothelium in cognitive
function, aging and hypertension has gained much atten-
tion recently [33-38] Central endothelial function can be
assessed indirectly by the response of CBF to changes in
end-tidal CO2[39] Ang II plays a critical pathophysiologi-
cal role in impairing endothelial function, especially in
those with hypertension[30-32,40] Therefore we are sug-
gesting that hypertension is associated with RAS activa-
tion and endothelial function impairment that in turn are
associated with abnormal CBF regulation and cognitive
and executive function impairments.
Multiple observational and experimental studies,
although not universally consistent, have shown that use
of antihypertensives may provide cognitive protection in
the elderly population[41] However, it is not known if
they provide this effect solely by lowering blood pressure
or via an additional class specific effect[42] Based on our
suggested pathway from hypertension to cognitive
impairment, we are hypothesizing that antihypertensives
that inhibit the activity of RAS lower this risk beyond just
lowering blood pressure. They also restore endothelial
function and cerebral blood flow regulation leading to
further cognitive protection.
Drugs that inhibit RAS include angiotensin converting
enzyme inhibitors (ACEI) and angiotensin receptor
blockers (ARB). ACEI block ACE and decrease Ang II pro-
duction, whereas ARB block the angiotensin receptor type
1 but not type 2[43,44] ACEI and ARB may be protective
against cognitive and physical impairment in hyperten-
sives [45-50] In an observational study of 1,220 Italian
individuals with heart failure, treatment with ACEI was
associated with improved cognitive performance[51] The
Perindopril Protection Against Recurrent Stroke Study
indicated that perindopril (ACEI) reduced the risk of inci-
dent cognitive impairment in those with a previous his-
tory of stroke[46] In the Cognition and Prognosis in the
Elderly trial, treatment with candesartan (ARB) was asso-
ciated with a lower rate of cognitive decline only in thoseBMC Geriatrics 2009, 9:48 http://www.biomedcentral.com/1471-2318/9/48
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with Mini-Mental Status-Examination Scores between 24
and 28 compared to placebo, but not the whole sam-
ple[52] Other antihypertensives such as diuretics and cal-
cium channel blockers may increase RAS activity through
increasing renin levels[53,54] Diuretics, which produce
similar lowering blood pressure effect to ACEI and ARB,
activate RAS. Studies suggest that diuretics do not demon-
strate a cognitive protective effect [55].
In addition to their effect on cognitive function, animal
and human studies have suggested that both ACEI and
ARB are associated with improved cerebral hemodynam-
ics[56,57] In spontaneously hypertensive rats, treatment
with ARB was associated with improved cerebral autoreg-
ulation[58], reduction in CBF decline after middle cere-
bral artery occlusions,[59] and normalization of the
production of nitric oxide[60]. Treatment with cande-
sartan or captopril (ACEI) was also associated with a
smaller infract size after middle cerebral artery occlu-
sion[59] In addition, ARB has a specific anti-aging effect
on the cardiovascular system. For example, losartan, but
not diuretic-based antihypertensive treatments, reduced
heart to body weight ratio in old but not young Wister-
Kyoto rats[61] In humans, studies on the effect of ACEI or
ARB on cerebral hemodynamics are scarce. Work by our
coauthor, Dr. Lipsitz, demonstrated that ACEI, but not
other antihypertensives, improve CBF and cerebral vaso-
reactivity in cognitively intact hypertensive older
adults[62,63] ARB have also been found to improve cere-
bral autoregulation in hypertensive patients with
strokes[64] and diabetes[65] Preliminary studies suggest
that drugs that inhibit RAS improve endothelial func-
tion[66] For example, in hypertensive patients treated
with a beta-blocker, switching to an ARB resulted in
improved endothelial function, measured by flow medi-
ated dilatation[67]
Of the two classes, recent studies have shown that ARB
may be superior to ACEI or diuretics in providing neuro-
protection and improving vascular function[45,64,68]
Both type 1 and 2 angiotensin receptors are present in the
brain and have opposing effects: type-1 leads to vasocon-
striction, whereas type 2 receptor leads to vasodilatation,
neuronal differentiation, apoptosis and axonal regenera-
tion[69] ARB, but not ACEI inhibit the type-1 receptors
leaving the type-2 receptors active. This may translate to
greater cerebral dilatation and a superior protective effect.
In fact, preliminary evidence suggests that ARB are supe-
rior to other antihypertensives in their ability to reduce
the risk of stroke[70] They also provide greater anti-
atherosclerotic effect; measured by intima-media thick-
ness, compared to ACEI in elderly hypertensive individu-
als[71] Therefore, we hypothesize that ARB are superior to
ACEI in their cognitive and endothelial function effect
measured by TCD at the middle cerebral artery, which in
turn is superior to HCTZ, a drug that activates RAS.
Our objective is to conduct a double-blind randomized
controlled clinical trial, the antihypertensives and vascu-
lar, endothelial, and cognitive function (AVEC), to com-
pare 1 year treatment of 3 antihypertensives (lisinopril,
candesartan, or hydrochlorothiazide (HCTZ)) in their
effect on memory and executive function, cerebral blood
flow, and central endothelial function of seniors with
hypertension and early objective evidence of executive or
memory decline.
Methods/Design
Experimental design and participants
The overall experimental design of the AVEC trial is a 3-
arm double blind randomized controlled clinical trial. A
total of 100 community eligible individuals with hyper-
tension and early cognitive impairment are being
recruited from the greater Boston area. Evaluated at the
cardiovascular research laboratory at the Institute for
Aging Research, and then randomized to candesartan, lisi-
nopril, or HCTZ ("active control") for 12 months. Cur-
rently recruitment efforts include various community
activities, faith-based community events, health fairs,
advertisements, and mail out announcements. Figure 1
describes the flow from screening to study exit. The Insti-
tutional Review Board at the Institute for Aging Research
at Hebrew Rehabilitation Center for Aged approved the
study and all participants provide written informed con-
sent.
Inclusion Criteria include
(1) 60 years or older; (2) hypertension: defined as a systo-
lic blood pressure (SBP) of 140 mm Hg or greater or
diastolic blood pressure (DBP) 90 mm Hg or greater or
receiving antihypertensive medications; (3) early cogni-
tive impairment without dementia defined as executive
impairment (measured by the executive clock draw test
(CLOX)) [72] or early memory impairment (measured by
the repeatable battery for the assessment of neuropsycho-
logical status) [73]. Both of these tests are brief (total of 15
minutes), have been validated in elderly populations and
have standardized norms[72,74]
Exclusion criteria include
(1) Intolerance to 2 of the study medications; (2) SBP
>200/DBP >110 mm Hg if not on treatment or SBP > 180/
DBP > 100 mm Hg if on antihypertensive therapy; (3)
Mini-Mental-Status-exam (MMSE)<20 or a clinical diag-
nosis of dementia or Alzheimer's disease; (4) elevated
serum creatinine or serum potassium at baseline; (5)
receiving >2 antihypertensives; (6) Comorbid illnesses
(congestive heart failure, diabetes mellitus stroke); and
(7) inability to perform the study procedures.BMC Geriatrics 2009, 9:48 http://www.biomedcentral.com/1471-2318/9/48
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Individuals who are currently receiving 1 or 2 antihyper-
tensives are eligible to participate if the participant and
the primary care provider are willing to taper their antihy-
pertensives. The medication is tapered while carefully
monitoring blood pressure using a standard protocol in
our laboratory [63].
The intervention
The intervention is treatment with lisinopril, candesartan,
or HCTZ. The goal of the intervention is to achieve blood
pressure control defined as SBP < 140 mm Hg and DBP <
90 mm Hg. The starting dose is 10 mg increased to 20 mg
then 40 mg of lisinopril; 8 mg increased to 16 mg then 32
mg of candesartan; and 12.5 mg increased to 25 mg of
HCTZ. Titration occurs every 2 weeks until blood pressure
is <140/90 mm Hg. If blood pressure is still not control-
led, long acting nifedipine is added at 30 mg increased to
60 mg and 90 mg in 2 week increments. If still not con-
trolled, a beta-blocker is added at 12.5 mg increased to 25
mg and 50 mg of long-acting metoprolol.
Randomization and blinding
The randomization is performed using computer gener-
ated random numbers leading to a random allocation
sequence. This random allocation is performed at the cen-
tral pharmacy at Hebrew SeniorLife. Both study personnel
and participants are blinded to the group assignment.
Study phases
The following are the study phases:
(i) Screen: This includes: (1) informed consent, (2) 2
seated blood pressure measurements separated by 5 min-
utes, (3) executive function and memory assessments, and
(4) inclusion/exclusion criteria assessment. Eligible par-
ticipants are scheduled for the Baseline visit. If they are
receiving antihypertensives, they are also given the auto-
mated blood pressure measurement machine. Instruc-
tions on using the machine, tapering the
antihypertensives, frequency of measurements, a diary,
and appropriate phone numbers are provided.
(ii) Baseline evaluation and randomization: during this
visit, participants undergo blood pressure measurements,
cognitive assessments, physical measures, and TCD proce-
dures. Randomization to one of the 3 antihypertensive
medications occurs after the baseline visit.
(iii) Follow up: Participants are then seen every 2 weeks
until blood pressure control (<140/90 mm Hg) is
achieved. During these visits, blood pressure measure-
ments, medication adjustments and assessments of
potential adverse events are completed. Participants are
then followed for 12 months after achieving target blood
pressure (<140/90 mm Hg) and evaluated at 1, 3, 6, and
12 months. At each evaluation, blood pressure, adverse
events, pill count (to assess compliance), use of other
medications is assessed, and blood samples are drawn as
outlined in Table 1. A re-evaluation including cognitive
assessment, physical measures, TCD, and medical exami-
nation are performed at 6 and 12 months.
Experimental Procedures and measures
(i) Health Interview and exam: Demographics, social his-
tory and habits, family history, medication inventory[75],
physical activity using the Physical Activity Scale for the
Elderly[76] and Instrumental Activities of Daily Living
(IADL) [77] data will be collected. Blood pressure is meas-
Study flow of the AVEC trial from the screening tothe study  exit Figure 1
Study flow of the AVEC trial from the screening 
tothe study exit.
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ured using standardized procedures according to the
American Heart Association guidelines[78,79]: the partic-
ipant is in the sitting position, rested for 5 minutes, no caf-
feine or smoking 2 hours prior to measurement,
appropriate cuff size (covering 60% of upper arm length
and 80% of arm circumference), correct cuff placement
(1-2 inches above brachial pulse on bare arm), and use of
the bell of the stethoscope or an automatic calibrated
blood pressure machine. The systolic blood pressure is
defined as the pressure corresponding to the first
korotkoff sound (K1) and the diastolic as the pressure cor-
responding to the last korotkoff sound (K5). Blood pres-
sure is measured in both arms and recorded. The arm with
the higher blood pressure is used throughout the study.
Two blood pressure readings are performed at each visit
and averaged per visit. The physical exam includes gait
speed (time to walk 4 meters conducted twice), height,
and weight measurements.
(ii) Neuropsychological assessment: The battery of tests
we chose for both screening and for the outcome meas-
ures was selected with the following considerations: brev-
ity, validation in a similar elderly population, and
sensitivity to detect impairment change over the study
period.
The screening tests include: the executive clock draw test
part 1 (CLOX1) and the Repeatable Battery for the Assess-
ment of Neuropsychological Status (RBANS) immediate
memory domain. We selected the CLOX1 as a screening
tool to detect those with executive function abnormalities.
The subject draws a clock in response to the examiner's
request. CLOX1 is sensitive to detect executive func-
tion[72] It has high internal consistency (Cronbach's
alpha = 0.82) and high between-rater reliability (r = 0.94,
p < 0.001)[72] A score 10 or less on CLOX1 is required for
eligibility[72] The RBANS immediate memory domain is
a brief test to assess memory [74]. Participants are asked
to repeat a list of 10 words and to repeat a short story. The
reliability coefficient is 88% for the immediate memory
domain. Those who score 1 standard deviation or below
the age-education-specific standardized mean on this test
will be eligible for the study. The Mini-Mental-Status-
Examination (MMSE) is used to exclude participants with
more advanced cognitive impairment. We selected this
test since those who score 20 or less are more likely to
have advanced cognitive impairment and dementia [80].
The inter-rater reliability of MMSE is 0.83[81]
The study outcome cognitive tests include Trail Making
test (A and B), Hopkins Verbal Learning Test - Revised
(HVLT-R), and the Digit Span Test. The Trail Making test
requires the connection of sequentially numbered circles
(A), and the connection of circles marked by numbers and
letters in an alternating sequence (B). This test is consid-
ered a benchmark of executive function. We selected this
test because it is sensitive to detect frontal lobe pathology
in patients with increased cerebrovascular and cardiovas-
Table 1: Study procedures at various stages of the AVEC trial
Visit Screen Enrollment Baseline Titrate* Follow-up
Months 0 2-4 weeks 1 2-3 3 6 12
Informed Consent/Eligibility X X X
Medication Inventory X X X X X X
Weight/Height XX X
Blood pressure
(2 every 5 min)
XX X X X X X
Psychological Assessment X X X X
Cerebrovascular Assessment X X X
Biochemical Measures X X X X X
Renin/Aldosterone XX X
Adverse Events Screening XX X X
If a titration of medication needed baseline will be performed after titration and before randomizationBMC Geriatrics 2009, 9:48 http://www.biomedcentral.com/1471-2318/9/48
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cular risk such as those with hypertension[8,10] The
HVLT-R is a 12-item list learning test in which individuals
are presented three learning and recall trials followed by a
delayed recall and 24 item recognition test. The HVLT-R
has been identified as an ideal memory measure for eld-
erly patients, and appropriate reliability and validity have
been shown in older individuals[82] We selected this test
because it is brief and allows us to identify abnormalities
in immediate vs. delayed recognition. The Digit Span Test
is a brief task that assesses immediate memory/attention.
It is administered using the standard format[83] It con-
sists of a series of digits of increasing length, some of
which are recited as presented, and some of which are to
be recited in the reversed order[84] We selected this test
since it can detect abnormalities with encoding.
(iii) Cerebral Blood Flow and its regulation: CBF autoreg-
ulation and cerebral vasoreactivity are assessed by TCD
using standard procedures described previously[85]
Blood flow velocity, and hence CBF, is measured at the
middle cerebral artery, which has a high correlation coef-
ficient (0.995) with invasive blood flow measurements
and high reliability in elderly subjects [86]. Beat to beat
heart rate and blood pressure are also measured by the
Finapress system and EKG[87] The Sit-to-Stand is used to
assess autoregulation by measuring continuous CBF,
blood pressure and heart rate in response to postural
changes in sitting and standing positions. Vasoreactivity is
measured by asking participants to deeply breath air with
8% CO2 [88] followed by hyperventilation. CBF, blood
pressure, and heart rate are continuously measured during
hyper and hypocapnea. The change in CBF relative to the
change in mean arterial pressure between sitting and
standing is used to measure autoregulation. The slope of
the relation between cerebrovascular conductance (mean
CBF/mean arterial blood pressure) for each R-R interval
and end-tidal CO2 i s  u s e d  t o  a s s e s s  C O 2 vasoreactivity
[88].
(iv) Biochemical measurement is done to monitor for
adverse events: hyperkalemia and renal failure. RAS activ-
ity is assessed using plasma renin activity and aldosterone
levels[89] Plasma aldosterone is measured by a radioim-
munometric assay (RIA). The Coat-A-Count procedure is
a solid phase radioimmunoassay, based on aldosterone
specific antibody immobilized to the wall of the polypro-
pylene tube. 125I-labelled aldosterone competes for a
fixed time with aldosterone in the patient sample for anti-
body sites. The sensitivity of this method is 16 pg/mL and
the precision is 4-10%[90]. Plasma renin activity is meas-
ured by competitive binding radioimmunoassay (RIA)
using the GammaCoat plasma renin activity RIA kit. The
determination involves an initial incubation of plasma to
generate angiotensin I, followed by quantification of angi-
otensin I by RIA. This technique is highly sensitive to low
levels of 0.01 ng/mL/hour and is precise to activity that is
less than 10%[91] In addition, a blood sample is drawn
for storage and DNA extraction for future genetic studies.
(v) Adverse events (AE): We are screening for potential
adverse events through self-report by the participant or
the next of kin. These include: dizziness, vertigo, light-
headedness, weakness, swollen lip or tongue or both, hos-
pitalizations, cough, falls, angioedema, renal insuffi-
ciency, and hyperkalemia with ACEI and ARB.
Hypokalemia may occur with HCTZ (potassium will be
supplemented). The incidence of cough with ACEI varies
but 5% is the most commonly reported rate [92].
Angioedema is extremely rare and occurs in about 0.68%
of patients treated with ACEI [93]. Screening for adverse
events occurs monthly by phone and during each visit
where measurements of serum potassium and creatinine
are performed. Emergency contact is also provided in case
adverse events occur in-between visits or communications
with the study personnel.
Statistical methods
All analyses will follow the intention-to-treat principle. We
will use Mixed Models since we have correlated repeat
observations and this procedure is not significantly
affected by missing data[94,95] We will compare the
change in the cognitive or CBF outcomes from baseline to
12 months between the three groups. The primary inde-
pendent variable is group assignment (candesartan, lisino-
pril, or hydrochlorothiazide). A sample size of 100 will
allow us to successfully complete at least 90 (10% drop
out, 30 per group) participants. A 30 per group (90 total
sample size) allows us to detect at least between group dif-
ferences in the change (from baseline to 12 months) of
0.46 standard deviation units (α = 0.05; power 80%). Fig-
ure 2 provides results of power analysis for the detectable
difference, sample size and power. Analysis for the safety
of the intervention will be conducted by comparing the
number of adverse events (cough, angioedema, leuko-
pinea, increase in serum creatinine by more than 1 mg/dl,
hyperkalemia (> = 5.5 meq/dl), hypotension (SBP < 100),
dizziness, falls and hospitalization) and the number of
participants who withdrew from the study in the three
groups using Analysis of Variance (ANOVA).
Discussion
Aging of the population will lead to increase prevalence of
hypertension and cognitive difficulties. To date, there are
no available data to provide guidelines for treatment of
hypertension in those with cognitive impairment. The
AVEC trial is the first study to explore impact of antihyper-
tensives in those who are showing early evidence of cog-
nitive difficulties that have not reached the threshold of
dementia. Observational studies have been conflicting
and some suggest that treatment of hypertension mayBMC Geriatrics 2009, 9:48 http://www.biomedcentral.com/1471-2318/9/48
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have a negative effect on cognitive function [96-98].
Therefore, a carefully performed clinical trial that selects
the appropriate population to study is critical to answer
the question about the impact of antihypertensives on
cognitive function.
The role of the RAS in aging is important because of the
available therapeutic intervention for this system.
Recently, RAS is a critical system in vascular biology and
recently in neuroscience. Identifying an impact of ACEI or
ARB on cognitive or cerebrovascular function will provide
additional mechanistic and therapeutic evidence of the
role of RAS in aging.
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